O ocrelizumabe traz resposta para pacientes com esclerose múltipla remitente recorrente logo nas primeiras semanas de tratamento e alivia a fadiga.
Portal Saúde Business24 de abril de 2017
Portal Saúde Business is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
